Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19)

Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030265

Enrollment

Unknown

Registered

2020-02-26

Start date

2020-02-24

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

High inflammation oXiris CRRT treatment group:oXiris CRRT treatment

High inflammation Conventional treatment group:Conventional treatment

Low inflammation conventional treatment group:Conventional treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years old; 2. It conforms to the diagnostic criteria of severe and critical type in "Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (6th Edition)"; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.; 2. Obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumor; 3. Continuous use of immunosuppressive agents or organ transplants in the past 6 months; 4. Use in vitro life support (ECMO, ECCO2R); 5. Patients are expected to die within 48 hours; 6. Patients with acute kidney injury and AKI stage 2 or above; 7. Any potential violation of test compliance or any other circumstance affecting safety and effectiveness evaluation that may exist, which the researchers believe is not suitable for patients participating in the study.

Design outcomes

Primary

Measure	Time frame
Inflammation factor;	—

Secondary

Measure	Time frame
7 day mortality;duration of mechanical ventilation;PD-1 expression of T cell;Absolute Lymphoblastic Counter;28 day mortality;T lymphocyte subsets;mDC, pDC, Treg;APACHE II Score;SOFA Score;Patient status score;Conversion rate of common and critical illness;pneumonia severity index, PSI;	—

Countries

China

Contacts

Public ContactKaijiang Yu

The First Affiliated Hospital of Harbin Medical University

drkaijiang@163.com+86 13303608899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026